Potravitug Demonstrates Statistically Significant Viral Clearance in Phase II BK Polyomavirus Trial, Paving Way for Pivotal Phase III
核心洞察
Memo Therapeutics' potravitug, a first-in-class anti-BKPyV monoclonal antibody, showed a 44.9% cumulative probability of viral clearance by week 20 versus 27.3% for matched controls (HR 1.89; p=0.028) in a propensity-score-matched analysis of the SAFE KIDNEY II trial.
The Phase II randomized, double-blind, placebo-controlled study employed an external control arm constructed from a multicenter kidney transplant cohort, with high-quality matching confirmed by absolute SMDs below 0.10 across all variables.
BK polyomavirus (搜索) reactivates in up to 50% of kidney transplant recipients, with up to 70% of viremic patients developing BKPyV nephropathy (搜索), yet no approved treatments currently exist for this significant infectious complication.
Memo Therapeutics AG (MTx) presented new analyses from its Phase II SAFE KIDNEY II trial of potravitug at the European Renal Association (ERA) Congress, revealing statistically significant improvements in viral clearance among kidney transplant recipients with BK polyomavirus (搜索) (BKPyV) infection. The data, presented by Dr. Abdolreza Haririan, Professor of Medicine at the University of Maryland and a trial investigator, bolster the case for potravitug as a potential first-in-class therapy in an indication with no currently approved treatments.
Propensity Score Matching Strengthens Comparative Evidence
The new analyses employed a propensity-score-matched external control arm constructed from a multicenter cohort of kidney transplant recipients, designed to contextualize the observed baseline BKPyV infection severity imbalance between groups in the original randomized, double-blind, placebo-controlled SAFE KIDNEY II trial. All potravitug-treated patients were successfully matched to controls, with absolute standard mean differences (SMDs) below 0.10, indicating high-quality matching across all variables and demonstrating substantial improvement in covariate balance between the potravitug and control cohorts. Post-matching baseline characteristics were highly comparable between groups.
Significant Antiviral Responses Across Key Endpoints
Potravitug-treated patients demonstrated significantly better antiviral responses on both the kinetics of viral reduction and clearance. At week 20, the cumulative probability of achieving at least a 1-log10 reduction in viral load was 64.1% for potravitug recipients compared with 44.8% for controls (HR 1.60; 95% CI: 1.00–2.58; p=0.05).
On the critical endpoint of viral clearance, separation of the Kaplan–Meier curves was observed early and maintained throughout the analysis period. The cumulative probability of clearing the virus by week 20 reached 44.9% in the potravitug group versus 27.3% in the matched control group (HR 1.89; 95% CI: 1.07–3.33; p=0.028).
A Significant Unmet Medical Need
BK polyomavirus (搜索) represents one of the most significant infectious complications following kidney transplantation. More than 100,000 kidney transplants are performed worldwide each year, and BKPyV can become reactivated in up to 50% of these patients. Among those who develop BKPyV viremia, up to 70% progress to BKPyV nephropathy (搜索) (BKPyVAN), a condition that significantly increases the risks of kidney loss and patient death. Despite this substantial disease burden, no approved therapies are currently available.
"BKPyV infection remains one of the most significant infectious complications following kidney transplantation, yet there are currently no approved treatments available to these patients," said Dr. Haririan. "These additional analyses strengthen the conclusions from the SAFE KIDNEY II trial, demonstrating a consistently favorable antiviral effect of potravitug versus matched controls, with statistically significant improvement observed for cumulative probability of viral clearance."
Regulatory Momentum and Next Steps
Potravitug, a highly potent human BKPyV-neutralizing monoclonal antibody, has already garnered regulatory attention. The U.S. Food and Drug Administration granted fast-track designation in May 2023, and the European Union awarded orphan drug designation in December 2025.
Erik van den Berg, CEO of MTx, commented: "These results further strengthen the clinical profile of potravitug and reinforce its potential to become the first targeted therapy for kidney transplant recipients with BK polyomavirus infection (搜索), an area with significant unmet medical need. We look forward to initiating our SAFE KIDNEY 3 program later this year and advancing potravitug toward patients who urgently need new treatment options."
The company plans to initiate the pivotal Phase III SAFE KIDNEY 3 trial in 2026. MTx estimates the market potential for potravitug at up to $2 billion annually.
Proprietary Discovery Platform
MTx's antibody development is underpinned by its proprietary DROPZYLLA® technology, an antibody repertoire copying engine with high-throughput screening capabilities. The platform retrieves and expresses antibody genes from millions of B cells at single-cell resolution while preserving cognate heavy- and light-chain pairing, enabling the development and manufacture of recombinant polyclonal IgG. Beyond potravitug, MTx is also focused on discovering novel antibody-target pairs in oncology.
MTx is a private company based in Schlieren/Zurich, backed by investors including Ysios Capital, Kurma Partners, Pureos Bioventures, Swisscanto, Vesalius Biocapital, and Adjuvant Capital.